topic

706 First-in-human phase 2 clinical trial of multiplex combination intratumoral immunotherapy (MCII) in patients with metastatic solid cancer (Abscopal 5001 trial)
David G Bostwick, Melanie M Wilk, Michael Cribbs, Julie Linton, Colleen E Ellis, Brian R Bostwick, Eugene C Rajaratnam, Laura M Galeazzi, Junqi Qian, Peter M Rydesky, Peter J Littrup

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 1) A801; DOI: 10.1136/jitc-2023-SITC2023.0706
707 Pseudostabilization of cancer (fibrous pseudotumor) is a common radiologic mimic of residual malignancy after multiplex combination intratumoral immunotherapy in the abscopal 5001 trial
David G Bostwick, Melanie M Wilk, Brian R Bostwick, Peter M Rydesky, Peter J Littrup

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 1) A802; DOI: 10.1136/jitc-2023-SITC2023.0707
708 A phase 1/2 study of rinatabart sesutecan (PRO1184), a novel folate receptor alpha-directed antibody-drug conjugate, in patients with locally advanced and/or metastatic solid tumors
Justin A Call, Ian Anderson, Ira Winer, Douglas Orr, Oladapo Yeku, Debra L Richardson, Jian Zhang, Elizabeth Lee, Gottfried Konecny, Ning Li, Sandip P Patel, Lin Wu, Jing Wang, Jun Zhang, Ying Cheng, Xiaohua Wu, Naomi Hunder, Lian Lu, Sharon Ma, Eric Song, Erika Hamilton

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 1) A803; DOI: 10.1136/jitc-2023-SITC2023.0708
709 Trial in progress: product characteristics and clinical trial design for T-Plex, a multiplexed, enhanced T cell receptor-engineered T cell therapy for solid tumors
Shrikanta Chattopadhyay, Antoine J Boudot, Ribhu Nayar, Hannah Bader, Andrew Ferretti, Tary Traore, Nancy Nabilsi, Jenny Tadros, Badr Kiaf, Yifan Wang, Victor Ospina, Alok Das Mahopatra, Zhonghua Zhu, Qikai Xu, Krista Daniels, Briana Zimmerman, Mollie Jurewicz, Amanda Kordosky, Chris Malcuit, Yun Wang, Marlyane Motta, Jim Murray, Ray Lockard, Cagan Gurer, Debora Barton, Gavin MacBeath

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 1) A804; DOI: 10.1136/jitc-2023-SITC2023.0709
710 Keynote-B59: dose escalation of a phase 1/2 first-in-human, open-label study of GI-101, a novel immunocytokine combining CD80-IL2v, in combination with pembrolizumab in advanced solid tumors
Byoung Chul Cho, Jae Lyun Lee, Sang Joon Shin, Byoung Yong Shim, Hyo Jin Lee, Jung-Yun Lee, John Powderly, Soohyeon Lee, Julia Cohen, Nari Yun, Mina Ham, Kyoyoung Lee, Hyunjin Kang, Kyoung-Ho Pyo, Jea Hwan Kim, Mi hyun Kim, Dong Kim, Myoung Ho Jang

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 1) A805; DOI: 10.1136/jitc-2023-SITC2023.0710
711 Development of oncolytic adenovirus Ad5/3-E2F-D24-hTNFa-IRES-hIL2 (TILT-123) for the treatment of solid tumours – from preclinical testing to phase I clinical trials
James Clubb, Victor Cervera-Carrascon, Katriina Peltola, Tuomo Alanko, Riitta Korpisaari, Marjut Jaakkola, Jorma Sormunen, Juha Kononen, Joao Manuel Santos, Santeri A Pakola, Elise Jirovec, Tatiana Kudling, Lyna Haybout, Dafne CA Quixabeira, Claudia Kistler, Riikka Havunen, Suvi Sorsa, Akseli Hemminki

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 1) A806; DOI: 10.1136/jitc-2023-SITC2023.0711
712 IMPORT-201 (IMP-MEL): a phase 1 first-in-human dose finding/randomized phase 2 study of a novel iNKT agonist (PORT-2) and pembrolizumab for advanced melanoma and non-small cell lung cancer (NSCLC)
Nicholas Coupe, David J Pinato, Justin Fairchild, Russell Poe, Carri Browne, Steven Innaimo, David Thompson, Uzi Gileadi, Carmela De Santo, Robert Kramer, Ian Walters, Mark R Middleton

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 1) A807; DOI: 10.1136/jitc-2023-SITC2023.0712
713 Nanrilkefusp alfa, a high-affinity IL-15Rβγ agonist, promotes an innate and adaptive anti-tumour inflammatory environment as single agent or combined with anti-PD-1 in patients with advanced cancers
Petr Danek, Ekaterina Simonova, Nada Podzimkova, David Bechard, Richard Sachse, Joachim Kiemle-Kallee, Ulrich Moebius, Radek Spisek, Irena Adkins, Martin Steegmaier, Lenka Palova Jelinkova

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 1) A808; DOI: 10.1136/jitc-2023-SITC2023.0713
714 Phase 1a trial of PLN-101095, an integrin αvβ8 and αvβ1 inhibitor, as monotherapy and in combination with pembrolizumab, in treatment-resistant patients with advanced or metastatic solid tumors
Adil Daud, Chris N Barnes, Susan Owen, Scott M Turner, Mario Sznol, Eric A Lefebvre, Hardean E Achneck

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 1) A809; DOI: 10.1136/jitc-2023-SITC2023.0714
715 ICT01 plus low dose SC IL-2 produces a robust anti-tumor immune activation in advanced cancer patients (EVICTION-2 Study)
Johann De Bono, Stéphane Champiat, Francois-Xavier Danlos, Martin Wermke, Volker Kunzmann, Aude De Gassart, Emmanuel Valentin, Marina Iche, Celine Leparquier, Maelle Mairesse, Patrick Brune, Katrien Lemmens, Daniel Olive, Paul Frohna

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 1) A810; DOI: 10.1136/jitc-2023-SITC2023.0715

Main menu

topic

Pages

Log in using your username and password

Main menu

Log in using your username and password

You are here

topic

Pages